VALENCIA, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering...
First U.K. case series demonstrates successful use of RECELL GO ® in 17 burn and reconstructive surgery patients Findings presented at the British Burn Association Annual Meeting support the role...
VALENCIA, Calif., May 17, 2026 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions, invites shareholders...
Avita Medical (NASDAQ:RCEL) reported first-quarter 2026 revenue growth and reaffirmed its full-year outlook as management said reimbursement conditions for its RECELL product are normalizing and demand...
VALENCIA, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ® , Inc. (NASDAQ: RCEL, ASX: AVH), a leading therapeutic acute wound care company delivering transformative solutions (“AVITA Medical,”...
Board appoints Cary Vance as President and Chief Executive Officer Follows successful interim tenure and thorough search process by the Board Jan Stern Reed elected as Chair of the AVITA...
RECELL GO ® receives regulatory clearance in Australia and New Zealand, enabling commercialization across both markets RECELL GO is AVITA Medical’s next-generation system that automates and standardizes...
Recognition highlights pioneering contributions to modern burn care including development of RECELL ® Spray-On Skin™ VALENCIA, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- AVITA Medical ®...
Mean time to graft reduced to 13.6 days vs. 33.2 days real-world benchmark (~20 day reduction) Median time to graft of 11 days, with grafting as early as 5 days Study ongoing with full dataset...
Agreement ensures rapid nationwide access to RECELL® for burn mass casualty incidents, providing BARDA access to 3,000 units any time over the 10-year contract VALENCIA, Calif., April 08, 2026...